看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
! N* H) k- n- Y. j7 o/ a" z( _* V4 q/ U/ |5 t2 m8 B$ _
6 | R$ a$ T7 {* I% ?0 g
Currently available feasibility data for possible combination strategies.
- `- \, B! q1 z9 J5 P————————————————————————————————- z P# Q2 v! y2 B& B- A7 ~* c
Combination Feasibility according to preliminary data : ]/ ^2 ^4 B1 }! }7 [
——————————————————————————————————
: ~9 N4 J4 C9 @ |% [( QBevacizumab + sorafenib Yes, reduced dose 2 a# r' g Y3 t& T4 g% _8 P
Bevacizumab + sunitinib† No + @( | h1 V6 I# A' g- ~- ?
Bevacizumab + temsirolimus Yes : k7 O' p9 A5 }8 @
Bevacizumab + everolimus Yes
' s# H' j k9 \2 ^" z7 F7 x5 ]- {Sorafenib + sunitinib ?
9 h' o' B# n# u& F$ LSorafenib + temsirolimus Yes, reduced dose
6 d+ W6 T( v) K# TSorafenib + everolimus Yes, reduced dose
6 x$ k! \5 C. Q: qSunitinib + temsirolimus† No 2 R% u0 @1 d* h$ n5 M$ [
Sunitinib + everolimus ? 8 |" s- l4 U& d8 L( ?
Temsirolimus + everolimus ? / Q. L& J+ H1 p& m7 m% z
————————————————————/ n5 B$ R5 y* u
†Led to US FDA warning.
" z' v' y2 J7 n5 W1 L' c?: As yet unattempted combination." z% j# I4 B* q# K
|
显身卡
